

OBJECTIVE

For Alberta clinicians to understand the approach to patients with dyspepsia, including non-invasive and invasive testing, alarm features suggesting significant pathology, and the role of *Helicobacter pylori*.

TARGET POPULATION

Adults

EXCLUSIONS

Pregnant or breastfeeding women

Children under 18 years of age

Dyspepsia is a symptom complex often associated with diseases of the upper gastrointestinal tract.¹ Dyspepsia symptoms include but are not limited to upper abdominal (epigastric) pain or discomfort, nausea, upper abdominal bloating, fullness, excessive burping or belching and early satiety.

Heartburn and regurgitation are symptoms most commonly associated with gastroesophageal reflux disease (GERD) but these symptoms can occur in dyspepsia together with the other listed upper GI symptoms.

RECOMMENDATIONS

- ✓ Inquire about precipitating factors (see [Table 1](#)) and attempt to correct (see [Algorithm](#)).

PRECIPITATING FACTORS

- NSAID/ASA use and other prescription medications (i.e., calcium channel blockers, bisphosphonates)
- Smoking and excessive alcohol use
- Dietary indiscretion (high fat meals)

Table 1: Precipitating Factors

- ✓ Assess with timely investigation* – preferably including endoscopy – for patients with:
 - New onset persistent dyspepsia in patients (> 50 years of age)
 - No response or limited response to acid-suppression treatment
 - Dyspepsia and any [alarm features](#)

*Consider imaging (barium swallow or CT scanning) if gastroscopy is not readily available.

- Alarm Features can be recalled by the mnemonic **VBAD**.

PRACTICE POINT

Patients ≥ 50 years of age with new onset of dyspepsia and/or those with evidence of alarm features should usually be investigated with endoscopy

- ✓ If symptoms (dominant heartburn, retrosternal burning, regurgitation) suggest GERD, refer to the Toward Optimized Practice (TOP) clinical practice guideline (CPG) for [Treatment of Gastroesophageal Reflux Disease \(GERD\)](#)

- ✓ **Consider testing for *Helicobacter pylori* with urea breath test (UBT) for dyspeptic patients:**

- <50 years of age without alarm features and with symptoms that do not suggest GERD

NOTE: Prior to testing for *H. pylori* with UBT, a three-day washout period is recommended following proton pump inhibitor (PPI) use and four weeks following antibiotic use (as per [Dynalife](#) or [CLS instructions](#)).

If UBT is positive refer to TOP's CPG [Treatment of *Helicobacter Pylori* Infection in Adults](#)

- ✓ If UBT is negative, consider trial of empiric acid suppression therapy (see [Empiric Therapy](#) below).

EMPIRIC ACID SUPPRESSION THERAPY

- ✓ PPI (first line) or H₂ receptor antagonist (H₂HR) (alternate)
- ✓ Reassess therapy in four to eight weeks
 - Symptoms resolved: stop treatment (or use medications as needed)
 - Symptoms improved: repeat treatment or consider twice daily PPI for another four to eight weeks
 - NO change in symptoms: consider further investigation or referral to gastroenterologist/endoscopist

PRACTICE POINT

Always consider pathologies other than upper gastrointestinal (UGI) tract (i.e., cardiac, hepatobiliary, colonic, musculoskeletal) in the differential diagnosis and investigate and treat accordingly

BACKGROUND

INTRODUCTION

Dyspepsia is a common complaint seen in primary care² and includes symptoms of upper abdominal discomfort or pain, retrosternal pain, nausea, bloating, fullness, excessive burping or belching, early satiety and heartburn amongst others. A definitive clinical diagnosis can be difficult to make based on these symptoms because few symptoms are discriminatory.

Many diseases can cause dyspepsia, including peptic ulcers (duodenal or gastric ulcers), GERD, cancer of the stomach and pancreas, and gallstones. However, many patients with dyspepsia will not have evidence of underlying organic disease – this is referred to as functional dyspepsia.³ Clinicians

can detect serious disease by identifying alarm features, testing selected patients for *H. pylori* and if necessary, investigations such as gastroscopy or diagnostic imaging can be performed.

DISEASE PREVALENCE

Dyspepsia is one of the most common symptoms that trigger a patient visit to a health care provider.⁴ Surveys in western societies have reported prevalence between 21 to 45%.⁵⁻⁷ In the United Kingdom, it has been estimated that approximately 40% of the population will experience dyspepsia at some point, about 20% used medications for symptom relief and 2% lost time from work because of dyspepsia.

The Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET–PE) study reported prevalence of significant endoscopic findings in patients presenting with uninvestigated dyspepsia in primary care. Clinically significant endoscopic findings from this study are as follows:⁸

Clinically significant endoscopic findings	Patient participants (all ages) N=1040
Erosive esophagitis	43%
Gastric or duodenal ulcers	5.3%
Malignancies (only found in patients over 50 with no alarm features)	(0.2%)

Table 2: Prevalence of significant endoscopic findings in patients presenting with uninvestigated dyspepsia

PATIENT HISTORY

If heartburn and regurgitation are the dominant symptoms, the patient should be treated as having GERD. However, many dyspepsia patients often present with non-specific symptoms, which may make diagnosis challenging. Consideration should be given to non-UGI causes (such as cardiac, hepatobiliary, colonic, musculoskeletal) and other organic pathologies.⁹

Patient history and physical examination should focus on detecting clinical alarm symptoms including (pneumonic ‘VBAD’) Vomiting, Bleeding, Anemia, Abdominal mass/anorexia/weight loss, Dysphagia/odynophagia). Other important features in the patient’s history include:

- Past or family history of relevant diseases (peptic ulcer disease, gastric cancer, cholelithiasis)
- Medication use: NSAID/ASA, calcium channel blockers, bisphosphonates
- Smoking, excessive alcohol intake
- Dietary indiscretion (high fat meals)

IDENTIFYING PATIENTS WHO DO REQUIRE EARLY ENDOSCOPY

As the incidence of gastric cancer begins to increase at the age of 50 years, it is reasonable to discuss endoscopy with patients over 50 years of age with new-onset dyspepsia.^{1,10} In addition, patients whose symptoms have failed to respond to empiric therapy should undergo gastroscopy.¹¹

Anecdotally, most patients with an upper gastrointestinal malignancy likely will have alarm features when they present for investigation and should have prompt gastroscopy.

NSAIDs/ASA

NSAID induced ulcer disease is a major epidemiologic problem.¹¹ As up to 10% of individuals using NSAIDs/ASA longer than 12 weeks have endoscopic evidence of ulceration, it is important to determine if the dyspeptic patient has a history of NSAID/ASA use. If there are no alarm symptoms and the patient is on NSAIDs/ASA, try to discontinue the NSAID/ASA.¹² If symptoms resolve, no further treatment is indicated. If NSAIDs/ASA cannot be discontinued consider lowest possible dose and/or initiate PPIs.¹³⁻¹⁵ If the symptoms persist despite treatment, further investigation and possible endoscopy is indicated.

There is a synergistic effect association between *H. pylori* infection and NSAIDs/ASA in causing peptic ulceration, and its complications.^{16,17} For this reason, patients in whom you anticipate requiring long term NSAIDs may benefit from searching for and eradicating *H. pylori*. (See TOP's [Treatment of Helicobacter Pylori Infection in Adults](#) CPG.)

LIFESTYLE MODIFICATIONS

Patients should be advised to stop smoking and reduce alcohol intake. Obvious dietary indiscretions should be addressed. However, there is no evidence that completely avoiding coffee, tea and/or chocolate is necessary.

GERD

Once patients with reflux-like symptoms are identified, they can be managed as per TOP's [CPG for Treatment of GERD](#).

TEST FOR *H. PYLORI* AND TREAT

The “test for *H. pylori* and treat” approach to dyspepsia is based on the knowledge that some dyspepsia patients have symptoms associated with duodenal or gastric ulcers, while a small proportion of other patients with non-ulcer dyspepsia have symptom improvement when their *H. pylori* infection is cured.^{18,19} One study reported that in Canadians with uninvestigated dyspepsia, using the test and treat approach resulted in more pain-free patients in one year than those patients treated with empiric acid suppression alone (50% vs 36%, ARD=14, NNT=7).¹⁸ If there are no alarm symptoms, a UBT should be performed and, if positive, the infection should be treated. (See TOP's clinical practice guideline [Treatment of Helicobacter Pylori Infection in Adults](#))

For those patients with dyspepsia who are *H. pylori* negative, evidence supports acid suppression therapy with PPIs or H₂RAs.¹⁹ Patients who test negative for *H. pylori* should be treated with a PPI or H₂RA for four weeks and then reassessed to determine whether their symptoms improved.¹¹ The evidence for effectiveness of prokinetic agents is limited and concerns exist about potential adverse events (including tardive dyskinesia²⁰ and prolonged QT syndrome²¹ and they are generally not recommended.²²

REFERENCES

1. British Society of Gastroenterology. Guidelines in gastroenterology. British Society of Gastroenterology; 1996 Sep.
2. Tougas G, Chen Y, Hwang P, Liu MM, Eggleston A. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. Domestic/International Gastroenterology Surveillance Study. *Am J Gastroenterol*. 1999 Oct;94(10):2845–54.
3. Tack J, Talley NJ. Functional dyspepsia--symptoms, definitions and validity of the Rome III criteria. *Nat Rev Gastroenterol Hepatol*. 2013 Mar;10(3):134–41.
4. Jones RH, Lydeard SE, Hobbs FD, Kenkre JE, Williams EI, Jones SJ, et al. Dyspepsia in England and Scotland. *Gut*. 1990 Apr;31(4):401–5.
5. Locke GR. The epidemiology of functional gastrointestinal disorders in North America. *Gastroenterol Clin North Am*. 1996 Mar;25(1):1–19.
6. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ. Dyspepsia and dyspepsia subgroups: a population-based study. *Gastroenterology*. 1992 Apr;102(4 Pt 1):1259–68.
7. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. *BMJ*. 1989 Jan 7;298(6665):30–2.
8. Thomson ABR, Barkun AN, Armstrong D, Chiba N, White RJ, Daniels S, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. *Aliment Pharmacol Ther*. 2003 Jun 15;17(12):1481–91.
9. Talley NJ. Spectrum of chronic dyspepsia in the presence of the irritable bowel syndrome. *Scand J Gastroenterol Suppl*. 1991;182:7–10.
10. American Gastroenterological Association medical position statement: evaluation of dyspepsia. *Gastroenterology*. 1998 Mar;114(3):579–81.
11. Veldhuyzen van Zanten SJO, Bradette M, Chiba N, Armstrong D, Barkun A, Flook N, et al. Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. *Can J Gastroenterol J Can Gastroenterol*. 2005 May;19(5):285–303.
12. Internal Clinical Guidelines Team (UK). Dyspepsia and Gastro-Oesophageal Reflux Disease: Investigation and Management of Dyspepsia, Symptoms Suggestive of Gastro-Oesophageal Reflux Disease, or Both [Internet]. London: National Institute for Health and Care Excellence (UK); 2014 [cited 2016 May 6]. (National Institute for Health and Care Excellence: Clinical Guidelines). Available from: <http://www.ncbi.nlm.nih.gov/books/NBK248065/>
13. Yeomans N, Lanas A, Labenz J, van Zanten SV, van Rensburg C, Rácz I, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. *Am J Gastroenterol*. 2008 Oct;103(10):2465–73.

14. Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). *Heart Br Card Soc.* 2011 May;97(10):797–802.
15. Scheiman JM, Herlitz J, Veldhuyzen van Zanten SJ, Lanas A, Agewall S, Nauclicr EC, et al. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. *J Cardiovasc Pharmacol.* 2013 Mar;61(3):250–7.
16. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. *Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc.* 2006 Feb;4(2):130–42.
17. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. *Lancet Lond Engl.* 2002 Jan 5;359(9300):14–22.
18. Chiba N, Van Zanten SJOV, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. *BMJ.* 2002 Apr 27;324(7344):1012–6.
19. Veldhuyzen van Zanten SJO, Chiba N, Armstrong D, Barkun A, Thomson A, Smyth S, et al. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. *Am J Gastroenterol.* 2005 Jul;100(7):1477–88.
20. Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. *Arch Intern Med.* 1993 Jun 28;153(12):1469–75.
21. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. *N Engl J Med.* 2004 Sep 9;351(11):1089–96.
22. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. *Cochrane Database Syst Rev.* 2006;(4):CD001960.

SUGGESTED CITATION

Toward Optimized Practice (TOP) Dyspepsia Working Group. 2009 Jan. Diagnosis and treatment of chronic undiagnosed dyspepsia in adults: clinical practice guideline. Edmonton, AB: Toward Optimized Practice. Available from: <http://www.topalbertadoctors.org>

This work is licensed under a [Creative Commons Attribution-Noncommercial-Share Alike 2.5 Canada License](https://creativecommons.org/licenses/by-nc-sa/2.5/ca/) with the exception of external content reproduced with permission for use by TOP.

For more information see www.topalbertadoctors.org


GUIDELINE COMMITTEE

The committee consisted of representatives of family medicine, general practice, gastroenterology, pediatric gastroenterology, pathology, radiology, radiation oncology, infectious disease, the public and the Alberta Pharmaceutical Association.

Dyspepsia	June 2000
Reviewed	November 2001
Revised	January 2005
Revised	2009
Minor Revision	2015

ALGORITHM

DIAGNOSIS AND TREATMENT OF CHRONIC UNDIAGNOSED DYSPEPSIA IN ADULTS[†]



[†] Excluding pregnant or breastfeeding women and children under 18 years